WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of …
MF Oliver, JA Heady, JN Morris, J Cooper - 1984 - cabidigitallibrary.org
This final report on mortality amongst men in the WHO cooperative trial of the prevention of
ischaemic heart disease (IHD) by clofibrate takes the follow-up a further 4 years to the end of
1982. Mean observation was 13.2 years, 5.3 in the trial and 7.9 afterwards. In 208 000 man-
years 1788 deaths were recorded. In the 877 new deaths reported here, there was an
excess of 9 deaths in the high-cholesterol control group compared with the clofibrate-treated
group. In the whole period there were 70 (11%) more deaths in the clofibrate-treated group …
ischaemic heart disease (IHD) by clofibrate takes the follow-up a further 4 years to the end of
1982. Mean observation was 13.2 years, 5.3 in the trial and 7.9 afterwards. In 208 000 man-
years 1788 deaths were recorded. In the 877 new deaths reported here, there was an
excess of 9 deaths in the high-cholesterol control group compared with the clofibrate-treated
group. In the whole period there were 70 (11%) more deaths in the clofibrate-treated group …
WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up.
MF Oliver, JA Heady, JN Morris, J Cooper - 1981 - cabidigitallibrary.org
In a further report on mortality among men in the WHO cooperative trial of the primary
prevention of ischaemic heart disease (IHD) by clofibrate, mean observation was 5.3 years
in the trial and 4.3 afterwards; 911 deaths were recorded in 150 000 man-years. There were
25% more deaths in the clofibrate-treated group than in the comparable, high serum
cholesterol, control group and there was an excess in the treated group in all 3 participating
centres. Mortality from all causes was higher in the treated group than in the high-cholesterol …
prevention of ischaemic heart disease (IHD) by clofibrate, mean observation was 5.3 years
in the trial and 4.3 afterwards; 911 deaths were recorded in 150 000 man-years. There were
25% more deaths in the clofibrate-treated group than in the comparable, high serum
cholesterol, control group and there was an excess in the treated group in all 3 participating
centres. Mortality from all causes was higher in the treated group than in the high-cholesterol …